Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura) in Patients With Vitiligo

Treatment with ruxolitinib cream (Opzelura) resulted in facial repigmentation at Week 24, characterized by a significant proportion of patients achieving =75% improvement from baseline in the facial

Related Keywords

Delaware ,United States ,Ohio ,Erica Cech ,Catalina Loveman ,David Rosmarin ,Christine Chiou ,Jim Lee ,European Academy Of Dermatology ,Dermatology Department At Tufts Medical Center ,Group Vice ,Drug Administration ,Exchange Commission ,European Medicines Agency ,Incyte Corporation ,Vitiligo Area Scoring ,Vitiligo Area Scoring Index ,European Academy ,Vitiligo Noticeability Scale ,Group Vice President ,Inflammation Autoimmunity ,Vice Chair ,Dermatology Department ,Tufts Medical ,Mississippi River ,Incyte Dermatology ,Looking Statements ,Incyte ,Nnounces ,Bull ,Results ,Rom ,Hase ,True ,Program ,Valuating ,Ruxolitinib ,Cream ,Opzelura ,Patients ,Ith ,Vitiligo ,